4D Molecular Therapeutics (FDMT)

• Market cap: $214M
• 1 day: -0.64%
• 5 days: -3.13%
• 1 month: -0.64%
• 3 months: -41.93%
• 6 months: -69.45%
• Year to date: -20.41%
• 1 year: -82.48%
• 5 years: -88.54%
• 10 years: -88.54%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Employees: 201

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

132% more call options, than puts

Call options by funds: $858K | Put options by funds: $370K

16% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 44

15% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 27

2% more funds holding

Funds holding: 139 [Q3] → 142 (+3) [Q4]

10.27% less ownership

Funds ownership: 111.64% [Q3] → 101.37% (-10.27%) [Q4]

58% less capital invested

Capital invested by funds: $628M [Q3] → $262M (-$366M) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $6 29% upside
• Avg. target: $29 525% upside
• High target: $46 891% upside

5 analyst ratings

• positive: 4 80%
• neutral: 0 0%
• negative: 1 20%

Chardan Capital Geulah Livshits 14% 1-year accuracy 7 / 51 met price target	547% upside $30	Buy Maintained	11 Feb 2025
HC Wainwright & Co. Matthew Caufield 20% 1-year accuracy 12 / 59 met price target	676% upside $36	Buy Reiterated	10 Feb 2025
Morgan Stanley Judah Frommer 30% 1-year accuracy 3 / 10 met price target	29% upside $6	Underweight Maintained	13 Jan 2025
Leerink Partners Mani Foroohar 31% 1-year accuracy 5 / 16 met price target	482% upside $27	Outperform Maintained	13 Jan 2025
B of A Securities Tazeen Ahmad 27% 1-year accuracy 8 / 30 met price target	891% upside $46	Buy Maintained	18 Dec 2024